1. Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study
- Author
-
David Schanzlin, Steve Klein, James P. Owen, Mark A. Bullimore, Mohinder M. Merchea, and Thao N. Yeh
- Subjects
Adult ,medicine.medical_specialty ,business.industry ,Meibomian gland dysfunction ,Meibomian Glands ,Meibomian gland ,Hyperthermia, Induced ,Middle Aged ,Ophthalmology ,medicine.anatomical_structure ,Multicenter study ,Eye dryness ,Tears ,medicine ,Humans ,Dry Eye Syndromes ,Ocular Surface Disease Index ,Prospective Studies ,Adverse effect ,Prospective cohort study ,business ,Meibomian Gland Dysfunction ,Clear liquid - Abstract
OBJECTIVES To assess 1-week and 1-month efficacy of Systane iLux thermal pulsation treatment for meibomian gland dysfunction (MGD). METHODS This prospective, nonrandomized, open-label, multicenter study enrolled 30 adult patients (60 eyes) who had a Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score greater than 6 and total meibomian gland secretion (MGS) score equal to or less than 12 in each eye. All participants received thermal pulsation treatment bilaterally. Primary efficacy measures included MGS score (sum of grades for 15 glands graded on a scale of 0-3; 0 [no secretion], 1 [inspissated], 2 [cloudy], and 3 [clear liquid]) and tear breakup time (TBUT). Secondary efficacy measures were SPEED and Ocular Surface Disease Index (OSDI) scores. RESULTS The mean age of patients was 52.9±11.9 years. After 1 week, the mean MGS score improved significantly from 4.1±3.1 to 15.8±7.1 (right eye, OD) and 3.7±3.1 to 16.7±7.6 (left eye, OS); mean TBUT improved significantly from 4.9±4.1 to 8.4±3.6 (OD) and 5.2±4.2 to 8.9±3.9 (OS); and mean SPEED and OSDI scores improved significantly from 16.1±5.3 to 7.2±6.1 and 45.2±21.3 to 19.0±16.8, respectively (all P
- Published
- 2021